About Frontier
About Frontier Medicines
Delivering breakthrough medicines for patients by mapping the proteome for covalency
We believe in going big on behalf of patients. Deploying a groundbreaking scientific approach by combining chemoproteomics and AI for covalent drug discovery, we have identified opportunities across over 90% of the human proteome, enabling us to take a near limitless precision medicine approach. We are focused on translating these novel insights into meaningful new treatments against high-impact, difficult-to-drug targets.
Chris Varma, Ph.D.
Co-founder, Chairman and CEO
Get to know us!
Allison Roberts, Ph.D.
Principal Scientist, Chemical Biology
As a scientist in the Chemical Biology department at Frontier, I am responsible for developing various mass spectrometry and chemical biology techniques to drive our drug discovery pipeline and expand our chemoproteomics platform.
Partners
Global Partnership with AbbVie for Select E3 Ligases and Certain Oncology and Immunology Targets
Frontier Medicines has a global strategic collaboration with AbbVie to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against certain high-interest, difficult-to-drug protein targets.
Under the multi-year collaboration, AbbVie and Frontier will utilize The Frontier™ Platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets. Whereas conventional drug discovery methodologies have been primarily successful against a relatively discrete set of target classes, chemoproteomics-based screening in relevant cellular contexts has the potential to enable targeting of a significantly broader range of proteins. By selecting certain immunology and oncology targets for the collaboration that are considered well validated but currently inaccessible, the collaboration has the potential to develop highly differentiated and efficacious therapeutics.
Investors
